FDA Offers Speedier Approvals to Drug Companies Aligning With 'National Priorities'

Follow Drugslib on

By Stephanie Brown HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 18, 2025.

via HealthDay

WEDNESDAY, June 18, 2025 -- On Tuesday, the U.S. Food and Drug Administration announced a new initiative to offer expedited reviews for new medicines, an initiative that will apply to drugs that administration officials determine promote "the health interests of Americans."

The initiative, referred to as the Commissioner's National Priority Voucher program, allows drug developers to participate in a novel FDA priority program. The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10 to 12 months to one to two months.

This new process convenes experts from various FDA offices for a team-based review, which differs from the standard review system in which a drug application is sent to numerous FDA offices. Clinical information will be reviewed by a multidisciplinary team of physicians and scientists. This team will prereview all submitted information and then convene for a one-day "tumor board-style" meeting.

"Using a common-sense approach, the national priority review program will allow companies to submit the lion's share of the drug application before a clinical trial is complete so that we can reduce inefficiencies. The ultimate goal is to bring more cures and meaningful treatments to the American public," FDA Commissioner Marty Makary, M.D., M.P.H., said in a statement. "As a surgical oncologist, we often made multidisciplinary decisions with a team of doctors on major life-and-death questions for patients, incorporating the latest medical studies in a one-day tumor board-style discussion. This voucher harnesses that model to deliver timely decisions for drug developers."

Specific criteria will be used to make the vouchers available to companies aligned with what the FDA considers national health priorities: confronting health crises in the United States; providing more innovative cures for the American people; fulfilling unmet public health needs; and expanding domestic drug manufacturing as a national security issue.

Qualifying drug manufacturers must submit the chemistry, manufacturing, and controls section of their application and the draft labeling at least 60 days prior to submitting their final application. They will also be expected to keep in communication and provide prompt responses to FDA inquiries during the review process.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-06-19 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords